Literature DB >> 21664789

Efficacy of continuing medical education to reduce the risk of buprenorphine diversion.

Michelle R Lofwall1, Martha J Wunsch, Paul A Nuzzo, Sharon L Walsh.   

Abstract

As office-based opioid dependence treatment (OBOT) has grown in the United States, postmarketing surveillance data reveal increased reports of buprenorphine misuse and diversion. It is important that doctors understand buprenorphine clinical pharmacology and engage in practices to decrease risk of misuse, diversion, and other adverse events. This study evaluated the efficacy of continuing medical education (CME) in two U.S. regions with surveillance signals of buprenorphine misuse/diversion. Four surveys (before, on-site, and 1 and 3 months post CME) evaluated physician characteristics, practice behaviors, and buprenorphine pharmacology and legislative knowledge. The results show that physicians had limited addictions training. Knowledge and practice behaviors significantly improved after the CME, which should enhance the quality of OBOT and may decrease risk of buprenorphine misuse and diversion from their practices. Mandatory CME targeting OBOT-certified physicians could have a positive impact on patient and public health outcomes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664789     DOI: 10.1016/j.jsat.2011.04.008

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  12 in total

1.  Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process.

Authors:  Carrie M Farmer; Dawn Lindsay; Jessica Williams; Amanda Ayers; James Schuster; Alyssa Cilia; Michael T Flaherty; Todd Mandell; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2015-04-06       Impact factor: 3.716

Review 2.  What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose.

Authors:  Tamara M Haegerich; Leonard J Paulozzi; Brian J Manns; Christopher M Jones
Journal:  Drug Alcohol Depend       Date:  2014-10-14       Impact factor: 4.492

3.  Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study.

Authors:  Todd Molfenter; Maureen Fitzgerald; Nora Jacobson; Dennis McCarty; Andrew Quanbeck; Mark Zehner
Journal:  J Psychoactive Drugs       Date:  2019-02-07

4.  Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.

Authors:  Raminta Daniulaityte; Russel Falck; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2011-10-28       Impact factor: 4.492

5.  Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.

Authors:  Michelle R Lofwall; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2012-06-15       Impact factor: 4.492

6.  Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?

Authors:  Molly Doernberg; Noa Krawczyk; Deborah Agus; Michael Fingerhood
Journal:  Subst Abus       Date:  2019-04-22       Impact factor: 3.716

7.  Buprenorphine Prescribing Availability in a Sample of Ohio Specialty Treatment Organizations.

Authors:  Todd Molfenter; Carol Sherbeck; Mark Zehner; Sandy Starr
Journal:  J Addict Behav Ther Rehabil       Date:  2015

Review 8.  Buprenorphine Prescribing: To Expand or Not to Expand.

Authors:  Xiaofan Li; Daryl Shorter; Thomas R Kosten
Journal:  J Psychiatr Pract       Date:  2016-05       Impact factor: 1.325

9.  Sources of Misused Prescription Opioids and Their Association with Prescription Opioid Use Disorder in the United States: Sex and Age Differences.

Authors:  Ji-Yeun Park; Li-Tzy Wu
Journal:  Subst Use Misuse       Date:  2020-01-24       Impact factor: 2.164

Review 10.  A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Authors:  Michelle R Lofwall; Sharon L Walsh
Journal:  J Addict Med       Date:  2014 Sep-Oct       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.